Elisa Mead Jorgensen, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gynecologic Surgical Procedures | 2 | 2018 | 336 | 1.010 |
Why?
|
| Hysterectomy | 4 | 2019 | 927 | 0.770 |
Why?
|
| Vulvar Diseases | 1 | 2017 | 61 | 0.590 |
Why?
|
| Homeodomain Proteins | 5 | 2016 | 2417 | 0.570 |
Why?
|
| Venous Thromboembolism | 2 | 2018 | 1668 | 0.540 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2017 | 171 | 0.530 |
Why?
|
| Endometriosis | 1 | 2023 | 834 | 0.510 |
Why?
|
| Phenols | 1 | 2016 | 501 | 0.420 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 577 | 0.410 |
Why?
|
| Laparoscopy | 6 | 2020 | 2121 | 0.390 |
Why?
|
| Perioperative Care | 1 | 2018 | 997 | 0.380 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 840 | 0.360 |
Why?
|
| Foot Deformities, Congenital | 1 | 2009 | 59 | 0.340 |
Why?
|
| Estrogens | 1 | 2016 | 1562 | 0.340 |
Why?
|
| Hand Deformities, Congenital | 1 | 2009 | 145 | 0.320 |
Why?
|
| Postoperative Complications | 3 | 2019 | 15244 | 0.310 |
Why?
|
| Urogenital Abnormalities | 1 | 2009 | 261 | 0.280 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 2407 | 0.230 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 3639 | 0.220 |
Why?
|
| Endometrium | 3 | 2021 | 424 | 0.200 |
Why?
|
| Endometrial Hyperplasia | 1 | 2021 | 96 | 0.190 |
Why?
|
| Expert Testimony | 1 | 2023 | 356 | 0.190 |
Why?
|
| Laparotomy | 2 | 2019 | 474 | 0.180 |
Why?
|
| Genital Diseases, Female | 1 | 2020 | 197 | 0.170 |
Why?
|
| Adnexal Diseases | 1 | 2019 | 102 | 0.160 |
Why?
|
| Salpingectomy | 1 | 2017 | 52 | 0.150 |
Why?
|
| Tubulin Modulators | 1 | 2017 | 110 | 0.150 |
Why?
|
| Sterilization, Tubal | 1 | 2017 | 87 | 0.150 |
Why?
|
| Peptides | 1 | 2009 | 4392 | 0.150 |
Why?
|
| Cysts | 1 | 2021 | 676 | 0.140 |
Why?
|
| Receptors, LHRH | 2 | 2008 | 159 | 0.140 |
Why?
|
| Vinblastine | 1 | 2017 | 490 | 0.140 |
Why?
|
| Reoperation | 1 | 2023 | 4200 | 0.110 |
Why?
|
| Prednisone | 1 | 2017 | 1567 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 516 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2019 | 1188 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2021 | 1351 | 0.100 |
Why?
|
| Female | 17 | 2023 | 379592 | 0.100 |
Why?
|
| Biopsy | 1 | 2023 | 6756 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 1581 | 0.100 |
Why?
|
| Co-Repressor Proteins | 1 | 2011 | 194 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2008 | 1185 | 0.090 |
Why?
|
| Uterine Diseases | 1 | 2011 | 135 | 0.090 |
Why?
|
| Smoke | 1 | 2011 | 226 | 0.090 |
Why?
|
| Polyps | 1 | 2011 | 189 | 0.090 |
Why?
|
| Embryo Implantation | 1 | 2011 | 272 | 0.080 |
Why?
|
| Mullerian Ducts | 1 | 2009 | 198 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2017 | 2107 | 0.080 |
Why?
|
| Pain | 1 | 2023 | 4961 | 0.080 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2009 | 242 | 0.080 |
Why?
|
| Clinical Competence | 2 | 2020 | 4681 | 0.080 |
Why?
|
| Adenosine Triphosphatases | 1 | 2011 | 836 | 0.070 |
Why?
|
| Uterus | 1 | 2011 | 710 | 0.070 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 1097 | 0.070 |
Why?
|
| Protein Binding | 2 | 2016 | 9387 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 5867 | 0.070 |
Why?
|
| Fertility | 1 | 2011 | 770 | 0.070 |
Why?
|
| Massachusetts | 1 | 2018 | 8662 | 0.070 |
Why?
|
| Mutation | 2 | 2009 | 29717 | 0.060 |
Why?
|
| CCAAT-Binding Factor | 1 | 2004 | 23 | 0.060 |
Why?
|
| Infertility, Female | 1 | 2011 | 784 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2011 | 7721 | 0.060 |
Why?
|
| Humans | 15 | 2023 | 742088 | 0.060 |
Why?
|
| Hysteroscopy | 2 | 2017 | 102 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2019 | 3738 | 0.060 |
Why?
|
| Internship and Residency | 2 | 2020 | 5774 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2018 | 4595 | 0.060 |
Why?
|
| Response Elements | 1 | 2004 | 311 | 0.060 |
Why?
|
| Syndrome | 1 | 2009 | 3248 | 0.050 |
Why?
|
| Hypogonadism | 1 | 2008 | 798 | 0.050 |
Why?
|
| Adult | 8 | 2021 | 213712 | 0.050 |
Why?
|
| Risk Factors | 2 | 2018 | 72145 | 0.050 |
Why?
|
| Pedigree | 1 | 2009 | 4646 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 4187 | 0.050 |
Why?
|
| Incidence | 1 | 2018 | 20928 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 12071 | 0.050 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 45 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2019 | 21719 | 0.040 |
Why?
|
| Pregnancy | 3 | 2017 | 29087 | 0.040 |
Why?
|
| Middle Aged | 5 | 2021 | 213127 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2020 | 77098 | 0.040 |
Why?
|
| Family | 1 | 2009 | 3144 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 2019 | 235 | 0.040 |
Why?
|
| United States | 3 | 2020 | 69693 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 23320 | 0.040 |
Why?
|
| Fallopian Tubes | 1 | 2017 | 182 | 0.040 |
Why?
|
| Ureter | 1 | 2019 | 374 | 0.040 |
Why?
|
| Pregnancy, Unplanned | 1 | 2017 | 95 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 2061 | 0.030 |
Why?
|
| Gynecology | 1 | 2020 | 509 | 0.030 |
Why?
|
| Mice | 4 | 2016 | 81045 | 0.030 |
Why?
|
| Contraception | 1 | 2017 | 356 | 0.030 |
Why?
|
| Postmenopause | 1 | 2021 | 2461 | 0.030 |
Why?
|
| Nuclear Localization Signals | 1 | 2011 | 80 | 0.020 |
Why?
|
| Connecticut | 1 | 2011 | 363 | 0.020 |
Why?
|
| Aged | 2 | 2021 | 162944 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2011 | 12164 | 0.020 |
Why?
|
| Child | 1 | 2017 | 77478 | 0.020 |
Why?
|
| Animals | 4 | 2016 | 168561 | 0.020 |
Why?
|
| Neurons | 1 | 2008 | 9325 | 0.020 |
Why?
|
| Pregnancy Rate | 1 | 2011 | 643 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2008 | 171 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 9639 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 964 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2019 | 9846 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2008 | 276 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2008 | 500 | 0.020 |
Why?
|
| Cell Size | 1 | 2008 | 643 | 0.020 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2004 | 32 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2008 | 1309 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 2633 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2004 | 300 | 0.010 |
Why?
|
| Cell Count | 1 | 2008 | 1831 | 0.010 |
Why?
|
| Cell Line | 2 | 2011 | 15994 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2011 | 3001 | 0.010 |
Why?
|
| Logistic Models | 1 | 2018 | 13403 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2011 | 13029 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 2088 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2011 | 2968 | 0.010 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2004 | 892 | 0.010 |
Why?
|
| Prevalence | 1 | 2018 | 15194 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 4823 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2011 | 3678 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 40450 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 57683 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 5212 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2020 | 53187 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 9735 | 0.010 |
Why?
|
| Binding Sites | 1 | 2004 | 6115 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 3504 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 19223 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 12797 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 62966 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 9581 | 0.010 |
Why?
|
| Male | 2 | 2020 | 349538 | 0.000 |
Why?
|
| Young Adult | 1 | 2011 | 56350 | 0.000 |
Why?
|